BEAT - BioTelemetry Inc Stock Price, Fair Value and News
1.95USD-0.06 (-2.99%)Delayed as of 10 May 2024, 02:06 pm ET
Market Summary
USD1.95-0.06
Delayedas of 10 May 2024, 02:06 pm-2.99%
BEAT Stock Price
View Fullscreen
BEAT RSI Chart
BEAT Valuation
BEAT Price/Sales (Trailing)
BEAT Profitability
BEAT Fundamentals
BEAT Earnings
Breaking Down BEAT Revenue
52 Week Range
1.883.74
(Low)(High)
Last 7 days
-8.2%
Last 30 days
-5.6%
Last 90 days
11.6%
Trailing 12 Months
-9.8%
How does BEAT drawdown profile look like?
BEAT Financial Health
BEAT Investor Care
Tracking the Latest Insider Buys and Sells of BioTelemetry Inc
Filter Transactions| Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
|---|---|---|---|---|---|---|
| Sep 29, 2023 | de urioste george | sold | -11,330 | 2.06 | -5,500 | - |
| Sep 28, 2023 | de urioste george | sold | -16,320 | 2.04 | -8,000 | - |
| Sep 27, 2023 | de urioste george | sold | -3,869 | 2.11 | -1,834 | - |
| Sep 26, 2023 | de urioste george | sold | -10,450 | 2.09 | -5,000 | - |
| Sep 22, 2023 | de urioste george | sold | -5,288 | 2.21 | -2,393 | - |
| Sep 21, 2023 | de urioste george | sold | -241 | 2.41 | -100 | - |
| Sep 20, 2023 | de urioste george | sold | -2,172 | 2.46 | -883 | - |
| Sep 18, 2023 | de urioste george | sold | -12,300 | 2.46 | -5,000 | - |
| Sep 15, 2023 | de urioste george | sold | -10,373 | 2.43 | -4,269 | - |
| Sep 14, 2023 | de urioste george | sold | -10,850 | 2.17 | -5,000 | - |
Which funds bought or sold BEAT recently?
View All Details| Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
|---|---|---|---|---|---|---|
| May 06, 2024 | Warberg Asset Management LLC | added | 32.61 | -3,870 | 19,011 | -% |
| May 03, 2024 | Larson Financial Group LLC | unchanged | - | -213 | 2,725 | -% |
| May 02, 2024 | KESTRA PRIVATE WEALTH SERVICES, LLC | added | 9.89 | 3,744 | 196,832 | -% |
| May 02, 2024 | Smith Salley Wealth Management | added | 25.00 | 75,000 | 545,000 | 0.04% |
| May 01, 2024 | CONCOURSE FINANCIAL GROUP SECURITIES, INC. | sold off | - | - | - | -% |
| May 01, 2024 | CONCOURSE FINANCIAL GROUP SECURITIES, INC. | sold off | - | - | - | -% |
| Apr 25, 2024 | Bank of New York Mellon Corp | sold off | -100 | -42,864 | - | -% |
| Apr 23, 2024 | Spectrum Asset Management, Inc. (NB/CA) | unchanged | - | -7,633 | 97,882 | 0.04% |
| Apr 16, 2024 | Pasadena Private Wealth, LLC | reduced | -0.93 | -15,856 | 179,979 | 0.04% |
| Mar 11, 2024 | VANGUARD GROUP INC | added | 69.97 | 543,089 | 1,176,230 | -% |
Are Funds Buying or Selling BEAT?
Calls
Puts
Net Call Options
No. of Funds
Unveiling BioTelemetry Inc's Major ShareHolders
| Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
|---|---|---|---|---|---|
| Oct 25, 2023 | strome mark e | 12.0% | 3,150,000 | SC 13D | |
| Aug 28, 2023 | public ventures, llc | 9.41% | 2,624,910 | SC 13D | |
| Jun 02, 2023 | schwartzberg andrew | 7.33% | 1,899,536 | SC 13D | |
| Feb 13, 2023 | ionic ventures, llc | 0.52% | 41,519 | SC 13G/A | |
| Jan 10, 2023 | sabby management, llc | 3.40% | 271,788 | SC 13G/A | |
| Feb 03, 2022 | ionic ventures, llc | 9.99% | 813,522 | SC 13G/A | |
| Mar 10, 2021 | arrowmark colorado holdings llc | 0.0% | 0 | SC 13G/A | |
| Feb 16, 2021 | arrowmark colorado holdings llc | 11.4% | 3,927,595 | SC 13G/A | |
| Feb 10, 2021 | vanguard group inc | 10.16% | 3,486,540 | SC 13G/A | |
| Jan 25, 2021 | blackrock inc. | 15.6% | 5,368,860 | SC 13G |
Recent SEC filings of BioTelemetry Inc
View All Filings| Date Filed | Form Type | Document | |
|---|---|---|---|
| May 09, 2024 | 10-Q | Quarterly Report | |
| May 03, 2024 | 424B5 | Prospectus Filed | |
| May 02, 2024 | 8-K | Current Report | |
| Apr 30, 2024 | DEF 14A | DEF 14A | |
| Apr 19, 2024 | PRE 14A | PRE 14A | |
| Mar 20, 2024 | 10-K | Annual Report | |
| Feb 05, 2024 | 8-K | Current Report |
Peers (Alternatives to BioTelemetry Inc)
| Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
|---|---|---|---|---|---|---|---|---|
| LARGE-CAP | ||||||||
UNH | 466.7B | 379.5B | 10.30% | 3.46% | 30.38 | 1.23 | 12.96% | -25.81% |
CI | 99.7B | 206.0B | -1.82% | 33.22% | 25.87 | 0.48 | 12.55% | -43.95% |
HCA | 84.3B | 66.7B | -2.18% | 15.50% | 15.4 | 1.26 | 9.59% | -4.59% |
CVS | 69.9B | 360.9B | -24.11% | -20.14% | 9.54 | 0.19 | 9.07% | 78.49% |
CNC | 41.4B | 155.5B | 6.79% | 16.14% | 15.15 | 0.27 | 6.34% | 84.42% |
DVA | 12.1B | 12.3B | 2.88% | 38.95% | 14.83 | 0.98 | 5.77% | 58.74% |
UHS | 11.9B | 14.7B | 3.23% | 25.09% | 14.57 | 0.81 | 7.99% | 19.23% |
| MID-CAP | ||||||||
CHE | 8.7B | 2.3B | -8.08% | 4.15% | 30.63 | 3.79 | 5.96% | 18.29% |
ACHC | 6.5B | 3.0B | -7.64% | 1.03% | -578.78 | 2.19 | 10.92% | -104.06% |
AMN | 2.3B | 3.8B | 0.76% | -34.62% | 10.95 | 0.61 | -27.73% | -52.50% |
AMEH | 2.2B | 1.5B | -8.15% | 19.83% | 35.09 | 1.51 | 19.34% | 40.15% |
| SMALL-CAP | ||||||||
ADUS | 1.7B | 1.1B | 7.65% | 29.55% | 26.45 | 1.6 | 11.45% | 30.74% |
BKD | 1.4B | 3.0B | 4.67% | 77.04% | -7.95 | 0.45 | 4.98% | 4.88% |
BEAT | 52.9M | - | -5.61% | -9.82% | -3.5 | - | - | -1.05% |
AMS | 19.9M | 21.3M | 3.03% | 6.99% | 37.29 | 0.93 | 8.00% | -62.25% |
BioTelemetry Inc News
Latest updates
BioTelemetry Inc Earnings Report: Key Takeaways & Analysis
Balance Sheet
(In Thousands)
| Balance Sheet | (In Thousands) | ||||||||||
| Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2020Q4 |
| Assets | -20.4% | 13,635 | 17,131 | 19,648 | 4,039 | 6,672 | 9,738 | 12,741 | 13,998 | 961 | - |
| Current Assets | -21.3% | 13,237 | 16,825 | 19,479 | 4,039 | - | - | - | - | - | - |
| Cash Equivalents | -21.6% | 12,688 | 16,189 | 19,184 | 3,594 | 6,549 | 9,274 | 11,201 | 13,192 | 795 | 24.00 |
| Net PPE | 34.4% | 344 | 256 | 144 | - | - | - | - | - | - | - |
| Liabilities | -8.1% | 1,097 | 1,194 | 1,019 | 1,665 | 932 | 770 | 514 | 588 | 6,148 | 4,836 |
| Shareholder's Equity | -21.3% | 12,538 | 15,937 | 18,629 | 2,374 | 5,740 | 8,968 | 12,227 | 13,410 | - | - |
| Retained Earnings | -12.5% | -41,431 | -36,825 | -32,946 | -22,186 | -18,474 | -14,895 | -11,370 | -9,224 | -7,139 | -4,796 |
| Additional Paid-In Capital | 2.3% | 53,966 | 52,759 | 51,572 | 24,559 | 24,213 | 23,862 | 23,596 | 22,633 | 1,952 | 11.00 |
| Shares Outstanding | 0% | 26,329 | 26,329 | 26,325 | 8,010 | 8,147 | 8,146 | 8,082 | 7,810 | 3,706 | 3,528 |
| Float | - | - | - | - | - | - | 6,424 | - | - | - | - |
Cashflow (Last 12 Months)
(In Thousands)
| Cashflow (Quarterly) | (In Thousands) | |||||||||||||||
| Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 |
| Cashflow From Operations | -21.2% | -3,463 | -2,858 | -2,098 | -4,023 | -3,114 | -2,955 | -2,725 | -1,929 | -2,339 | -2,441 | -365 | -269 | -155 | - | - |
| Share Based Compensation | 1.7% | 1,207 | 1,187 | 926 | 702 | 393 | 346 | 351 | 264 | 159 | 107 | 53.00 | 23.00 | 9.00 | - | - |
| Cashflow From Investing | 21.4% | -88.00 | -112 | 3,795 | -3,939 | - | - | - | - | - | - | - | - | - | - | - |
| Cashflow From Financing | - | - | - | 111 | 24,373 | 510 | - | - | 2.00 | 348 | 14,838 | 695 | 650 | 215 | - | - |
BEAT Income Statement
2023-12-31Statements of Operations - USD ($) | 12 Months Ended | |
|---|---|---|
Dec. 31, 2023 | Dec. 31, 2022 | |
| Operating Expenses: | ||
| General and administrative | $ 8,516,000 | $ 7,354,000 |
| Research and development | 6,798,000 | 5,677,000 |
| Total operating expenses | 15,314,000 | 13,031,000 |
| Loss from operations | (15,314,000) | (13,031,000) |
| Other income | ||
| Interest income | 675,000 | 66,000 |
| Other income | 0 | 3,000 |
| Total other income | 675,000 | 69,000 |
| Loss before provision for income taxes | (14,639,000) | (12,962,000) |
| Income tax provision | 0 | 0 |
| Net Loss | $ (14,639,000) | $ (12,962,000) |
| Net loss per share, basic (in dollars per share) | $ (0.72) | $ (1.59) |
| Net loss per share, diluted (in dollars per share) | $ (0.72) | $ (1.59) |
| Weighted average common shares outstanding, basic (in shares) | 20,333,280 | 8,168,516 |
| Weighted average common shares outstanding, diluted (in shares) | 20,333,280 | 8,168,516 |
BEAT Balance Sheet
2023-12-31Balance Sheets - USD ($) $ in Thousands | Dec. 31, 2023 | Dec. 31, 2022 |
|---|---|---|
| Current Assets: | ||
| Cash and cash equivalents | $ 16,189 | $ 3,594 |
| Prepaid expenses and other current assets | 636 | 445 |
| Total Current Assets | 16,825 | 4,039 |
| Property and equipment, net | 256 | 0 |
| Other assets | 50 | 0 |
| Total Assets | 17,131 | 4,039 |
| Current Liabilities: | ||
| Accounts payable and accrued expenses (includes related party $2 and $2, respectively) | 1,194 | 1,665 |
| Total Liabilities | 1,194 | 1,665 |
| Commitments (Note 7) | ||
| Stockholders’ Equity | ||
| Preferred Stock - $0.0001 par value; 10,000,000 shares authorized; 0 shares outstanding at December 31, 2023 and 2022 | 0 | 0 |
| Common stock - $0.0001 par value; 100,000,000 shares authorized; 26,329,032 and 8,009,743 shares issued and outstanding at December 31, 2023 and 2022 | 3 | 1 |
| Additional paid in capital | 52,759 | 24,559 |
| Accumulated deficit | (36,825) | (22,186) |
| Total Stockholders’ Equity | 15,937 | 2,374 |
| Total Liabilities and Stockholders’ Equity | $ 17,131 | $ 4,039 |
| CEO | Dr. Branislav Vajdic Ph.D. |
|---|---|
| WEBSITE | heartbeam.com |
| INDUSTRY | Healthcare Plans |
| EMPLOYEES | 10 |